Irradiated and activated autologous PBMCs induce expansion of highly cytotoxic human NK cells in vitro

Journal of Immunotherapy

Volumn 36, Issue 7, 2013, Pages 373-381

  Ahn, Yong Oon ^a   Kim, Saerom ^a   Kim, Tae Min ^a   Song, Eun Young ^a   Park, Myoung Hee ^a   Heo, Dae Seog ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Ex vivo expansion; Immune cell therapy; Natural killer cells

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D;

ADOPTIVE TRANSFER; ARTICLE; CELL ACTIVATION; CELL ASSAY; CELL EXPANSION; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; FEEDER CELL; FLOW CYTOMETRY; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IRRADIATION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PURIFICATION; RISK ASSESSMENT;

GAMMA RAYS; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LIGANDS; LYMPHOCYTE ACTIVATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, KIR; TRANSPLANTATION, HOMOLOGOUS;

EID: 84883236785     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182a3430f     Document Type: Article

References (36)

1. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7: 329-339.
2. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391: 795-799. (Pubitemid 28099678)
3. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295: 2097-2100. (Pubitemid 34229476)
4. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group. B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113: 726-732.
5. Yu J, Venstrom JM, Liu XR, et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for nonself HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood. 2009;113: 3875-3884.
6. Parham P, McQueen KL. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol. 2003;3: 108-122. (Pubitemid 37328689)
7. Loza MJ, Perussia B. The IL-12 signature: NK cell terminal CD56+high stage and effector functions. J Immunol. 2004; 172: 88-96. (Pubitemid 38020459)
8. Torelli GF, Guarini A, Maggio R, et al. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. Haematologica. 2005;90: 785-792. (Pubitemid 40897220)
9. Alici E, Sutlu T, Bjorkstrand B, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111: 3155-3162.
10. Carlens S, Gilljam M, Chambers BJ, et al. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol. 2001;62: 1092-1098. (Pubitemid 32971386)
11. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69: 4010-4017.
12. Klingemann HG, Martinson J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy. 2004;6: 15-22. (Pubitemid 38325115)
13. Peng BG, Liang LJ, He Q, et al. Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma. World J Gastroenterol. 2004;10: 2119-2123. (Pubitemid 39106972)
14. Cerboni C, Zingoni A, Cippitelli M, et al. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood. 2007;110: 606-615. (Pubitemid 47105399)
15. Eagle RA, Jafferji I, Barrow AD. Beyond stressed self: evidence for NKG2D ligand expression on healthy cells. Curr Immunol Rev. 2009;5: 22-34.
16. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314: 126-129. (Pubitemid 44547756)
17. Lim O, Lee Y, Chung H, et al. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo. PLoS One. 2013;8:e53611.
18. Gross O, Grupp C, Steinberg C, et al. Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine production. Blood. 2008;112: 2421-2428.
19. Gasser S, Orsulic S, Brown EJ, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436: 1186-1190. (Pubitemid 41232299)
20. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006;20: 123-137. (Pubitemid 43786166)
21. Romagnani C, Juelke K, Falco M, et al. CD56brightCD16- killer Ig-like receptor NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol. 2007;178: 4947-4955. (Pubitemid 46595277)
22. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev. 2006;214: 56-72. (Pubitemid 44707902)
23. Lopez-Verges S, Milush JM, Pandey S, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. 2010;116: 3865-3874.
24. Bjorkstrom NK, Riese P, Heuts F, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NKcell differentiation uncoupled from NK-cell education. Blood. 2010;116: 3853-3864.
25. Igarashi T, Wynberg J, Srinivasan R, et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin- like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004;104: 170-177. (Pubitemid 38879854)
26. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5: 201-214. (Pubitemid 40364822)
27. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436: 709-713. (Pubitemid 41117274)
28. Anfossi N, Andre P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25: 331-342. (Pubitemid 44224147)
29. Jiang W, Chai NR, Maric D, et al. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol. 2011;187: 781-790.
30. Cooper MA, Elliott JM, Keyel PA, et al. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci USA. 2009;106: 1915-1919.
31. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6: 383-393.
32. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol. 2011;8: 577-585.
33. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105: 3051-3057.
34. Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13: 98-107.
35. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116: 2411-2419.
36. Rose MJ, Brooks AG, Stewart LA, et al. Killer Ig-like receptor ligand mismatch directs NK cell expansion in vitro. J Immunol. 2009;183: 4502-4508.